Search
phosphate binder
Adverse effects:
- cardiovascular safety of sevelamer same as calcium acetate [2]
- hospital admission rates lowest for Velphoro 8.0 per 100 member months vs Fosrenol 9.9, Auryxia 9.5, sevelamer 10.5, Phosl0 11.3 [3]
Specific
aluminum hydroxide (Alternagel, Amphojel, Alu-Cap, Dialume, AlH3OH)
calcium acetate (PhosLo)
calcium carbonate (Tums, Oscal, Oyst-Cal)
ferric citrate (Auryxia)
lanthanum carbonate (La2[CO3]3, Fosrenol)
sevelamer (Renagel, Genzyme, Renvela)
sucroferric oxyhydroxide (Velphoro)
General
metabolic agent (metabolic modifier)
References
- Prescriber's Letter 22(8): 2015 (subscription needed)
Comparison of Phosphate Binders
Detail-Document#: 310810
http://www.prescribersletter.com
- Spoendlin J, Paik JM, Tsacogianis T et al
Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate
Binders in Patients 65 Years or Older With End-stage Renal Disease
Requiring Hemodialysis.
JAMA Intern Med. Published online May 6, 2019
PMID: 31058913
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2732117
- Monaco K
Phosphate Binder Type Matters in Dialysis -
Hospital admission rates, healthcare costs varied according to binder prescribed
MedPage Today. March 28, 2020
https://www.medpagetoday.com/meetingcoverage/nkf/85667
- Lindemann K et al
An Observational Analysis of Hospital Admissions and Total Member
Costs Associated with the Use of Various Phosphate Binders Used
in Dialysis Patients Included in ESCOs.
National Kidney Foundation (NKF) 2020; Abstract 209.